GBA2 and cystic fibrosis: Thus, the information derived from the literature and the data presented here provide evidence that different inhibitors, such as miglustat and Genz-529648, amitriptyline [14] and myriocin [21], that target GBA2, ASM and ceramide de novo synthesis, respectively, could represent therapeutic tools to reduce ceramide levels and limit excessive lung inflammation in CF patients (figure 10).